title: Peroxisome proliferator-activated receptor ligands in atherosclerosis.
abstract: In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-gamma agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-alpha agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-delta and the possibilities for the role of dual-binding agonists are examined.
authors.affiliation: Cardiovascular Biology Research Laboratory, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Viles-Gonzalez
authors.forename: Brian G
authors.initials: BG
authors.lastname: Choi
authors.forename: Valentin
authors.initials: V
authors.lastname: Fuster
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Badimon
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D004727:Endothelium / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008024:Ligands; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000378:metabolism*
chemical_list: D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors